iShares iBoxx $ Investment Grade Corporate Bond ETF (the Fund), formerly iShares iBoxx $ Investment Grade Corporate Bond Fund, is an exchange-traded fund (ETF). The Fund seeks to track the investment results of the Markit iBoxx USD Liquid Investment Grade Index (the Index), which is a rules-based index consisting of liquid, the United States dollar-denominated, investment-grade corporate bonds for sale in the United States. The Index may include large-, mid- or small-capitalization companies, and components primarily include consumer services, financial, and oil and gas companies. The components of the Index, and the degree to which these components represent certain industries, may change over time. The Index is a subset of the Markit iBoxx USD Corporate Bond Index. The Fund generally invests at least 90% of its assets in securities of the Index and at least 95% of its assets in investment-grade corporate bonds. The Fund's investment adviser is BlackRock Fund Advisors.
Basic Details
Issuer iShares
Fund NameiShares iBoxx $ Investment Grade Corporate Bond ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:LQD
Inception Date7/22/2002
Fund ManagerJames Mauro, Scott Radell
Phone+1-800-4742737
Fund Focus
Asset ClassFixed Income
BenchmarkiBoxx $ Liquid Investment Grade Index
CategoryCorporate
FocusInvestment Grade
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$35.48 billion
Average Daily Volume$8.59 million
Discount/Premium0.24%
ETF Expenses
Management Fee0.15%
Other Expenses0.00%
Total Expenses0.15%
Fee Waiver0.00%
Net Expenses0.15%
Administrator, Advisor and Custodian
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerJane Street
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.
